We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Concordia Rapped by FDA for ADHD Drug’s Misleading Sales Pitch
Concordia Rapped by FDA for ADHD Drug’s Misleading Sales Pitch
The FDA admonished Concordia Pharmaceuticals for a telephone sales pitch about its attention deficit hyperactivity disorder drug Kapvay that omits critical risk and dosing information.